Tempest Therapeutics (TPST) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

TPST Tempest Therapeutics

Watchlist

1.080
-0.020-1.82%

Close Nov 12 16:00 ET

1.040
-0.040-3.70%

Pre 04:25 ET

27.22MMarket Cap-675P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Tempest Therapeutics Inc : Piper Sandler Cuts Target Price to $5 From $8
Reuters9minutes ago
Tempest Therapeutics Reports Q3 EPS (41c), Consensus (36c)
TipRanks17:55 ET
Tempest Therapeutics Expects to Disclose Data From TPST-1495 Phase 1 Combination Arm in Patients With Advanced Endometrial Cancer in 2025 >TPST
Dow Jones16:47 ET
Tempest Therapeutics | 10-Q: Quarterly report
SEC16:34 ET · Announcements
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire16:21 ET
Express News | Tempest Therapeutics Q3 EPS USD -0.41 Vs. IBES Estimate USD -0.36
Reuters16:21 ET

Comments

小竜

17 hours ago

$Tempest Therapeutics (TPST.US)$

Teddy123

19 hours ago

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

$Tempest Therapeutics (TPST.US)$
12/11/2024 - 21:00
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter fro...

Trytosaveabit

20 hours ago

News

$Tempest Therapeutics (TPST.US)$ Reuters· just
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma